For example, in a phase I study of the oral pan-FGFR inhibitor LY2874455, of 15 GC patients evaluated for efficacy, only one patient had a partial response, and the patient’s tumour was not FGFR2 amplified [86]. The gene discussed is FGFR2; the disease is neoplasm.